HRS 2020: New Trial Data Support Medtronic’s Micra Pacemaker
Executive Summary
The Micra CED study showed a lower rate of complications with the Micra leadless pacemaker than transvenous single-chamber pacemakers.
You may also be interested in...
Medtronic ‘Plays Offense’ Despite Pandemic Challenges, Q1 Results Provide Optimism
Medtronic’s revenue of $6.5bn in the first quarter of fiscal 2021 represents a 17% fall year-over-year, but it still beat analysts’ projections.
Medtronic’s Micra Transcatheter Pacemaker Improves Cardiac Function In MARVEL 2
New clinical trial results show accelerometer-based atrial sensing with an automated, enhanced algorithm delivered by Medtronic’s leadless ventricular pacemaker can significantly improve atrioventricular synchrony in patients with sinus rhythm and atrioventricular block.
HRS 2017: Medtronic And Boston Scientific's Less-Invasive CRM Devices Perform As Hoped In Real-World Registries
Results from the post-approval trials of Medtronic's Micra Transcatheter Pacing System and Boston Scientific's S-ICD presented at the Heart Rhythm Society Scientific Sessions in Chicago show these "leadless" devices can be implanted in "real world" patients with acute outcomes similar to those of the pre-market trials that had more restrictive inclusion criteria.